PHARMX Technologies yesterday announced strong results for the financial year ending 30 Jun 2025, with total revenues of $7.5 million, up 13% on the previous corresponding period.

Growth was driven by increased account connections and transaction values across the Pharmx product suite.

EBITDA of $1.6 million represented a 13% decline on the previous financial year, due to significant investments in development, sales and marketing capability, and IT infrastructure.

However, these initiatives enabled the successful launch of the Supplier (PD 04 Apr) and Pharmacy (PD 27 Jun) Portals, and position the business for sustained future growth.

There was a 16% increase in supplier partners and a 7% increase in total accounts.

New brand additions include Pave (Thankyou brands), Healthy Life, Homart, and Canary IT, alongside strong growth with existing partners such as MCo Beauty.

CEO Tom Culver said he was “delighted with the FY25 results and with the team which delivered on a significant change agenda whilst continuing to accelerate our growth”.

“We remain dedicated to making a difference to healthcare by re-imagining how the industry connects,” Culver continued.

Culver noted that the company will maintain a focus on both system performance and security, enabling a growth strategy to ensure Pharmx remains a dominant player in the pharmacy industry.

“Backed by a strong balance sheet, a clear strategic roadmap, a highly experienced team, and favourable market conditions, Pharmx is well-positioned to capitalise on opportunities ahead and continue its growth trajectory,” Culver concluded.

MEANWHILE Fisher & Paykel Healthcare has released its guidance for the first half of FY26, noting strong growth of 13% across its Homecare and Hospital product groups.

Outlook for FY26 is still very positive, the business suggested, even after taking into account US tariffs imposed on hospital products sourced from New Zealand. KB

The post Pharmx delivers strong FY25 appeared first on Pharmacy Daily.